German HTA Rejects 'Major Added Benefit' Claim For Celgene's Imnovid
This article was originally published in Scrip
Executive Summary
Germany's health technology appraisal body IQWiG, the committee responsible for evaluating new medicines prior to pricing negotiations in the country, has given Celgene's multiple myeloma therapy Imnovid (pomalidomide) a rating of "no added benefit" over other available treatments.